Coya Therapeutics appoints a new CEO to lead its innovative Alzheimer's treatment development efforts. Photo via LinkedIn

Coya Therapeutics has named a new CEO. As of Nov. 1, Arun Swaminathan replaced Co-founder Howard Berman in the role. Berman has assumed the title of executive chairman, in which he will still remain active with the company.

Swaminathan started with Coya two years ago as chief business officer. This transition was planned, says the PhD-holding scientist and businessman.

“(Berman's) intent was that it was the right time to put in place a CEO that, as we move into the operational phases of the company, that can take the reins from him,” he tells InnovationMap.

Coya Therapeutics is a publicly traded biotechnology company that is working on two novel treatments for Alzheimer's disease. Coya's therapeutics, which are currently in trials, use regulatory T cells (T regs) to target both systemic- and neuroinflammation in patients.

InnovationMap: Berman has been a very visible CEO. Will you follow suit?

Arun Swaminathan: I think it's part of the CEO’s job to be visible and to communicate the value of our company to all the stakeholders out there. So yes, I do plan to be visible as well. Obviously, Howard as the founder had elements that he talked about, the foundational stories. I obviously will be doing less of that.

IM: What was your journey from the lab to the boardroom?

AS: I have a PhD from the University of Pittsburgh. I like to say that I grew up at Bristol Myers Squibb, so I started in a clinical pharmacology group at BMS, running clinical trials, but in the cardiovascular and metabolic space.

What happened was, as I was the study director on a diabetes trial there, and the data starts coming in for these early diabetic trials, and I got highly involved with the commercial folks at BMS in starting to plan out “What does the target profile look like? How is this going to play out in the real world?” You know, the marketing teams and commercial teams start engaging when clinical data is available, because they're starting to plan for the eventual launch of the product.

That gave me a lot of exposure to the commercial side of things, and I also got a lot of experience presenting to opinion leaders and others through that role. And I said, “What I really love is that intersection between science and business.” And so I think that was my moment.

Then I moved to business development and licensing, where I helped scan the universe for assets and talk to CEOs of companies like Coya as a junior person, trying to understand if there's something that we can bring into BMS to strengthen the pipeline of BMS. So that gave me exposure to deals, how deals are structured, how you negotiate a lot of that kind of stuff.

Then I said, “Look, if I want to be a complete person in biotech, I do need to go into more true commercial roles.” So I went into commercial strategy. I was involved in the commercial strategy for what is now known as Eliquis. Was back then known as apixaban. That’s still the generic name.

Then I led marketing for Orencia, a rheumatoid arthritis drug. So I went and got both strategic and tactical marketing experience at BMS, and then I used all of that experience, rounded up. I eventually ended up co-founding a company, and that's led me to the last nine years with smaller biotech companies. So that's my evolution and path. But I think my true moment of realization was about three years into my clinical role at BMS, when I said, what I really enjoy is translating good science into commercial value, and I think that's what excites me.

IM: Why is Houston an important part of Coya's success?

AS: It is important that Coya stays in Houston, because we have a very close association with Houston Methodist, we get a lot of our work, our early research work still done through Houston Methodist, through Dr. [Stanley] Appel's lab and through other experts. We absolutely have a special research agreement with Houston Methodist, so we have a very strong reason to be in Houston. So, we do not anticipate moving out of Houston.

------

This conversation has been edited for brevity and clarity.

Coya Therapeutics rang the closing bell at Nasdaq last week, celebrating six months since its IPO, new data from trials, and additions to its team. Photo via LinkedIn

Houston company with revolutionary neurodegenerative disease treatment shares milestones since IPO

ring that bell

After announcing its initial public offering earlier this year, a Houston therapeutics company has celebrated the milestone and announced recent growth as well.

Coya Therapeutics (Nasdaq: COYA) rang the closing bell last week. The clinical-stage biotech company, which has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again, announced the closing of its $15.25 million IPO in January.

"We launched our IPO into one of the toughest biotech capital markets in recent memory and are enormously grateful to all our investors for the confidence they then showed in our prospects," says Howard Berman, CEO and chairman of Coya, in a June 12 letter to stockholders. "I believe that to date, we’ve executed strongly against the goals we then established, and I remain excited about our future."

In the letter, Berman shares some of the recent clinical successes from two treatments — COYA 302, a treatment for ALS, and COYA 301, a treatment for Alzheimer’s Disease. Both treatments have seen strong clinical proof of concept data in the respective open-label studies.

Earlier this year, Coya expanded its C-suite to include Dr. Arun Swaminathan as chief business officer. He has over 20 years of hands-on health care business executive experience. Prior to Coya, Swaminathan served in the same role for Actinium Pharmaceuticals.

"Arun is actively engaged in exploring potential strategic opportunities across our portfolio of assets as we believe successful partnering efforts have the potential to enhance our scientific bona fides, leverage our technology into new areas of unmet medical need, and importantly, possibly secure upfront fees and associated non-dilutive funding," Berman writes in the letter. "We look forward to pursuing additional value creation catalysts that further highlight our entrepreneurialism and ability to execute, while maintaining focus on our core assets."

The latest addition to the Coya team is Guillaume Dorothée, who joins the company's scientific advisory board. A leading expert on the role that the immune system and peripheral-central immune crosstalk play in the pathophysiology of Alzheimer's, he's a tenured research director and team head in neuroimmunology at the French National Institute of Health and Medical Research in Paris.

“I am glad and honored to join such eminent scientists on the prestigious SAB of Coya Therapeutics," he says in a June 5 statement from Coya. "I am fully convinced that innovative Treg-based immunomodulatory approaches, as developed by Coya, are highly promising therapeutic strategies for the treatment of neurodegenerative disorders and other neuroinflammatory conditions. I will be happy to help Coya Therapeutics in this exciting endeavor.”

Recently, Berman joined the Houston Innovators Podcast to discuss Coya's mission and plan post IPO.


For Howard Berman, CEO and co-founder of Coya Therapeutics, commercializing his company is personal. Photo courtesy of Coya

Why this Houston innovator is racing to commercialize its unique treatment for neurodegenerative diseases

HOUSTON INNOVATORS PODCAST EPISODE 182

When Howard Berman sought out renowned Houston Methodist researcher and neurologist Dr. Stanley Appel, he was looking for treatment for his father, who was suffering from dementia. He wasn't looking for a job, but Dr. Appel had other ideas and asked Berman to meet with him.

"I was interested in what I could do for my dad," Berman says on the Houston Innovators Podcast, explaining how he took the meeting with Dr. Appel, who then presented him with some of his research. "By slide five my jaw had hit the ground.

"He had shown that he could stop the progression in one of his early trials of ALS," Berman says.

Not too long after that meeting, Berman, who founded digital health platform imaware, joined Dr. Appel to lead commercialization of Coya Therapeutics, a biotech startup that raised over $20 million in venture funding before going public a few months ago.

Coya has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again. Diseases like ALS, the company's focus right now, prevent T-regs from doing their job in controlling inflammation, and without these cells hard at work, the human body doesn't stand a chance in fighting autoimmune threats.

Berman, as co-founder and CEO, has been at the helm of the company leading it through both the fundraising and IPO processes. Coya's IPO occured in a tough market — only 12 biotech companies went public last year, he explains. To Berman, that just proves how passionate the team was about getting this product to those who need it.

"It really says something for the fortitude and our team to come together to make it happen," he says on the show. "We're able to deliver and execute in a difficult market climate.

"Once you're a public company, you have different expectations," he continues. "But you also have the opportunity to go out and attract additional investors in ways you can't do as a private company."

For Berman, whose father passed away earlier this year, it's a personal motivation that drives him to lead the company — as well as an opportunity to advance the city of Houston.

"The next number of years as we develop this therapeutic regimen for ALS, we have the potential to transform Houston into something more than it is currently," he says. "Our success will be the city's success."

Berman shares more of the Coya Therapeutics story on the podcast, as well as how he sees Houston's potential as an emerging hub for biotech. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

MD Anderson receives $10M gift to launch pancreatic cancer program

med funding

The University of Texas MD Anderson Cancer Center will be getting a significant boost in the fight against pancreatic cancer thanks to a recent gift from longtime supporters Zelma and William Reid. The medical system announced this month that a $10 million donation would help it establish a new Pancreatic Cancer High-Risk Interception Program.

“Philanthropic investments like this create opportunities to accelerate discoveries and pursue bold approaches to some of the most challenging cancers we face,” said Dr. Jeffrey E. Lee, president ad interim of UT MD Anderson, said in a news release. “We are deeply grateful to Zelma and Bill Reid for their generosity and enduring commitment. Their support will help advance innovative research aimed at intercepting pancreatic cancer earlier, when we have the greatest opportunity to improve outcomes for patients.”

Pancreatic cancer is one of the most deadly types of cancer. Despite being relatively rare, it ranks third in total deaths from cancer in the United States. Less than 10 percent of patients diagnosed with pancreatic cancer are still alive five years later.

Dr. Florencia McAllister, William Reid, Dr. Michael P. Kim, Zelma Reid, Dr. Manoop S. Bhutani, and Dr. Matthew H.G. Katz. Photo courtesy MD Anderson

The problem is often detection. The pancreas is located deep in the upper abdomen among many other organs, which can make spotting tumors difficult. Some blood tests can indicate pancreatic cancer, but it is usually not diagnosed until it spreads.

The new Pancreatic Cancer High-Risk Interception Program hopes to assemble new diagnostic techniques and patient screening tools to increase early detection. MD Anderson’s Dr. Michael P. Kim, associate professor of surgical oncology; Dr. Manoop S. Bhutani, professor of gastroenterology and hepatology; and Dr. Florencia McAllister, professor of gastrointestinal medical oncology and genetics, will lead the new program.

The team will rely on advanced imaging, molecular diagnostics, AI-driven assessment, and DNA testing to both create an at-risk patient population profile and hopefully help detect the cancer in its earliest stages. For instance, some of these tools will be able to monitor pancreatic cysts without invasive surgery.

“The ultimate goal is to intercept pancreatic cancer development or to initiate treatment earlier in the disease process, when patients have the best chance for successful outcomes,” Kim added in the release. “This gift will allow us to expand our research efforts, strengthen collaborations across disciplines and accelerate promising strategies to identify and intercept pancreatic cancer before it becomes life-threatening. We are incredibly thankful to the Reids for making this work possible.”

Axiom Space inks partnership to grow semiconductor crystals in orbit

space deal

Down in Webster, Texas, and high above the Earth, Axiom Space and Kansas-based Nitride Global Inc. will grow the next generation of semiconductor crystals in microgravity thanks to a new memorandum of understanding (MOU) signed earlier this month.

“Signing this MOU with Nitride Global reflects the growing commercial interest in producing advanced semiconductor materials in space,” Lucie Low, chief science officer for Axiom Space, said in a news release. “Their leadership in aluminium nitride (AlN) crystal growth and advanced packaging technologies, combined with Axiom Space’s capabilities in orbital infrastructure and mission integration, position us to demonstrate real commercial value in low-Earth orbit (LEO).”

This latest partnership builds on existing collaboration between Axiom and NitrideGlobal and NASA Ames Research Center.

Aluminium nitride crystals are part of the cutting-edge generation of semiconductors essential to emerging high-voltage transistors and also used in various medical technologies. Because of their high thermal stability, they can be used in a variety of environments and applications that have revolutionized everything from electric cars to the grids the cars run on.

However, the crystals are challenging to grow on Earth and face defects and size limitations due to gravity. Growing them in space can enhance their performance, according to NitrideGlobal. Microgravity allows them to grow more uniformly and with fewer defects, potentially resulting in larger, purer and more reliable crystals.

That’s where Axiom Space comes in. The company is developing Axiom Station, a successor to the International Space Station, where new research and manufacturing can be carried out.

“This MOU marks a pivotal milestone in our close partnership with Axiom Space that started as part of the NASA Small Business Innovation Research (SBIR) for AlN growth in space and is now expanding to usher the development of an innovation ecosystem,” Mahyar Khosravi, CEO of Nitride Global Inc., added in the release. “With Axiom Space’s leadership in the in-space manufacturing sector, this partnership will aim to deliver a platform for commercially viable manufacturing of [ultrawide bandgap materials] that will enable the next generation of semiconductor & microelectronics for terrestrial and planetary exploration uses.”

Houston's IAH lands on list of 15 most expensive U.S. airports

Travel Woes

Hold on to those carry-on bags: George Bush Intercontinental Airport is checking in as one of the 15 most expensive airports in the U.S., a new study has revealed.

The analysis from digital commerce and marketing platform ConsumerVoice.org compared the average domestic flight costs at the 50 largest U.S. airports, ranking them from highest to lowest. Flight price data was sourced from the U.S. Department of Transportation’s Bureau of Transportation Statistics (BTS) during the first and second quarters of 2026 and compared with the same period in 2025.

Washington Dulles International Airport in Virginia tops the list as the priciest major airport in the U.S, with domestic flights at IAD costing $534.34 on average. Charlotte Douglas International Airport in North Carolina comes in second place with an average fare cost of $527.79.

IAH lands at No. 13 nationwide, and it's the second most expensive in Texas, the findings show. The typical domestic flight from IAH costs $482.02, and they aren't getting any cheaper. Flights out of IAH are nine percent more expensive than they were a year ago, the report found. The average domestic flight cost $37.80 less in 2025.

Houstonians not only need to be prepared to spend a little extra money when booking their tickets; they'll also need to pack their patience, as IAH also ranks among the worst airports for flight delays and cancellations.

Travelers on a budget can save more on flights out of William P. Hobby Airport, if they're willing to make the drive. Travelers can save about 13 percent on their flights by flying through HOU instead of IAH, but there are other costs to take into consideration.

"Ground transportation, gas, and parking can eat into the difference, so factor these in when choosing the most economical departure airport," the report said.

HOU ranked as the No. 31 most expensive airport on the list with domestic flights coming in at $417.78 on average. Average fares at HOU are also nine percent more expensive than they were last year.

The top 10 priciest major airports in the U.S. are:

  • No. 1 – Washington Dulles International Airport
  • No. 2 – Charlotte Douglas International Airport
  • No. 3 – Detroit metro Wayne County Airport
  • No. 4 – Salt Lake City International
  • No. 5 – Minneapolis-St. Paul International
  • No. 6 – San Francisco International
  • No. 7 – John F. Kennedy International
  • No. 8 – Newark Liberty International
  • No. 9 – Dallas/Fort Worth International
  • No. 10 – Hartsfield-Jackson Atlanta International
---

This article originally appeared on CultureMap.com.